Form 4: SOPHIA GENETICS SA: Insider Sells Shares for Tax Withholding

SOPHIA GENETICS SA reports that Chief Scientific Officer Zhenyu Xu sold 608 ordinary shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

Summary

• Zhenyu Xu, Chief Scientific Officer of SOPHiA GENETICS SA, sold 608 ordinary shares on May 19, 2026.
• The sale was to satisfy tax withholding obligations upon the vesting of restricted stock units.
• These transactions were conducted under a pre-established Rule 10b5-1(c) trading plan.
• The weighted average sale price was $4.60, with individual sales ranging from $4.54 to $4.66.
• Following the transaction, Mr. Xu beneficially owns 626,280 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves an insider selling shares, the sale is explicitly for tax withholding purposes and conducted under a pre-established Rule 10b5-1 plan, mitigating concerns about discretionary selling.

Positives

• The sale was executed under a Rule 10b5-1(c) trading plan, indicating pre-planned and non-discretionary activity.
• The transaction was to cover tax withholding obligations, a common and expected event upon vesting of equity awards.
• The reporting person retains a significant beneficial ownership of 626,280 ordinary shares.

Negatives

• A sale of company stock by an insider, even for tax purposes, can sometimes be perceived negatively by the market.
• The sale represents a reduction in the insider's direct holdings, albeit for a specific obligation.

Risks

• Potential for negative market perception of insider selling, even if for tax purposes.
• The weighted average sale price indicates a range of prices, suggesting market fluctuations at the time of sale.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports a change in beneficial ownership.

Management Comments

• Sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that insider sales for tax withholding purposes under Rule 10b5-1 plans are common in the biotechnology and healthcare sectors, especially following significant vesting events of equity compensation. This filing is typical for such events and does not inherently signal a change in the insider's fundamental view of the company's prospects.

Stakeholder Impact

• Shareholders: The sale is unlikely to have a significant impact as it's a planned transaction for tax purposes and not indicative of a change in the insider's confidence in the company.
• Employees: The transaction relates to equity compensation vesting, which is a standard component of employee and executive compensation packages.
• Management: The Chief Scientific Officer is fulfilling a standard financial obligation related to their compensation.

Next Steps

• The reporting person will continue to hold their remaining beneficial ownership of 626,280 ordinary shares.
• The company may receive written requests for detailed transaction information from the issuer, security holders, or the SEC staff.

Key Dates

Keywords

SOPHIA GENETICS SA, Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, Rule 10b5-1, Zhenyu Xu, Chief Scientific Officer, Beneficial Ownership